191eTiP The Syrian TELE-TAT trial: A pragmatic, randomized study of tele-oncology for proactive adverse event management in patients receiving oral targeted therapies in a conflict zone

Read full text Summarise with VIRAT
Authors: A. Al-Bitar, Aya Alkhdr, Maryam Abo kharma, F.M. Aljojo, M. Manachi, M Alhalabi, R. Al-Khouli, Radwan Al-Ahmad
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

In conflict-affected, resource-limited settings such as Syria, the safe delivery of oral targeted anticancer therapies (OTATs), including tyrosine kinase inhibitors (TKIs) such as imatinib and ibrutinib, is severely compromised. Geographic barriers, security risks, and economic constraints make standard in-clinic monitoring for adverse events (AEs) largely inaccessible, leading to unmanaged toxicities, high rates of treatment interruption, and suboptimal outcomes. Proactive, low-technology tele-oncology offers a pragmatic solution to this critical gap in supportive care, but its efficacy in such extreme environments remains unproven.

Fields of Study & Subjects

Telemedicine and Telehealth Implementation Cancer survivorship and care COVID-19 and healthcare impacts

Publication details

Journal / source
ESMO Open
Volume
11
Pages
106198–106198
Publication date
1 April 2026
Language
EN